扩张型心肌病的治疗进展

Recent advance on the treatment of dilated cardiomyopathy

扩张型心肌病 (DCM )的基本治疗包括抗心力衰竭、心律失常及预防血栓栓塞等并发症。目前自身免疫被认为是DCM的主要病因 ,针对免疫介导心肌损伤的早期干预已成为DCM的主要治疗方法。在DCM早期应用地尔硫卓和 β 受体阻滞剂治疗 ,可以阻止免疫介导的心肌损害 ,改善患者的预后。己酮可可碱和免疫球蛋白的使用亦能改善患者的心功能。其他如生长激素的治疗有待探讨。

The primary therapy for dilated cardiomyopathy is to cure complications include congestive heart failure,arrhythmia and thromboembolism. Autoimmunity is considered to be the major cause of DCM. Intervention in early stage to aim directly at the myocardium impairment mediated by immunity is the main therapy for DCM. If treated with diltiazem and beta-adrenergic blockage in early stage of DCM, cardiac injure would be prevented and the prognosis improved. Cardiac function is improved in patients by pentoxifylline and immunoglobulin. The role of growth hormone in DCM is uncertained.